Researchers have produced a form of spirulina containing biologically active vitamin B12 at concentrations comparable to beef, potentially addressing a longstanding limitation of algae-based nutrition.
Spirulina, a widely consumed blue-green algae, has long been promoted as a plant-based source of vitamin B12. However, most commercial spirulina contains primarily “pseudo” B12, an inactive analog that the human body cannot use. The new work addresses that gap by manipulating the light conditions under which the algae is grown.
The research team reported that by carefully controlling the light spectrum and intensity used during cultivation, they were able to shift spirulina’s output toward producing true, biologically active B12 at levels approaching those found in beef. The researchers also described the production system as carbon-neutral, suggesting an environmental advantage over livestock-based B12 sources.
Vitamin B12 deficiency affects a significant portion of the global population, particularly people following plant-based diets, older adults, and individuals with certain medical conditions. Traditional supplementation relies heavily on fortified foods or synthetic B12, with animal products as the main dietary source.
Analysis:
If the findings hold under independent testing, the work could reshape how plant-based and sustainable B12 sources are evaluated. Spirulina’s reputation as a reliable B12 source has been undermined by multiple studies showing that its dominant B12-like compounds do not support human nutrition. A cultivation method that converts the algae into a meaningful B12 vehicle would represent a substantive advance over existing microalgae products.
The carbon-neutral framing also matters. Vitamin B12 production for supplements typically relies on bacterial fermentation, which carries its own energy and resource footprint, or on animal-derived sources tied to livestock production. A photoautotrophic system — one driven by light and carbon dioxide — could, if scaled, offer a lower-emission alternative, though commercial scalability, cost, and consistency remain untested in peer-reviewed industrial settings.
Independent verification of the B12 content, bioavailability in humans, and stability through processing and digestion will be necessary before any health or labeling claims can be supported.
Sources
Science Daily: https://www.sciencedaily.com/releases/2026/08/260829035227.htm
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Science Daily — source
